Epcoritamab 单药治疗复发或难治性滤泡性淋巴瘤(EPCORE NHL-1):单臂多中心研究的2期队列
EPCORE NHL-1 是一项多队列、单臂、1-2期试验,在15个国家88个中心开展。本文报告2期部分中复发或难治性滤泡性淋巴瘤患者(关键剂量扩展队列128例和周期1优化队列86例)的结果:关键队列总缓解率82.0%(105/128,95%CI 74.3-88.3),完全缓解率62.5%(80/128,95%CI 53.5-70.9);周期1优化队列细胞因子释放综合征发生率49%(42/86),无3级或以上事件。结论认为epcoritamab单药在多次复发或难治性滤泡性淋巴瘤中显示出有临床意义的活性,安全性可控。
要点
- 关键队列总缓解率82.0%(105/128,95%CI 74.3-88.3),完全缓解率62.5%(80/128,95%CI 53.5-70.9)。
- 关键队列3-4级治疗中出现的不良事件最常见为中性粒细胞减少32/128(25%)。
- 周期1优化队列细胞因子释放综合征发生率49%(42/86),无3级或以上,无免疫效应细胞相关神经毒性综合征报告。
核心结论
- Epcoritamab单药在多次复发或难治性滤泡性淋巴瘤患者中显示出有临床意义的活性,且安全性可控。
研究设计与样本
- EPCORE NHL-1为多队列、单臂、1-2期试验,在15个国家88个中心开展。
- 本文报告2期部分中复发或难治性滤泡性淋巴瘤患者,包括关键(剂量扩展)队列和周期1优化队列。
- 入组条件为年龄≥18岁、复发或难治性CD20+滤泡性淋巴瘤(1-3A级)、ECOG体能状态≤2、既往至少接受过2线治疗(包括抗CD20单克隆抗体和烷化剂或来那度胺)。
- 给药方案为皮下注射epcoritamab 48 mg,28天为一周期:第1-3周期每周一次,第4-9周期每两周一次,之后每4周一次直至疾病进展或不可接受毒性。
- 关键队列周期1采用阶梯剂量:第1天0.16 mg初始剂量,第8天0.80 mg中间剂量,后续48 mg全剂量,并预防性使用泼尼松龙100 mg。
主要发现
- 2020年6月19日至2023年4月21日,关键队列入组并治疗128例患者(中位年龄65岁[IQR 55-72];女性49例[38%],男性79例[62%]),中位随访17.4个月(IQR 9.1-20.9)。
- 关键队列总缓解率82.0%(105/128,95%CI 74.3-88.3),完全缓解率62.5%(80/128,95%CI 53.5-70.9)。
- 关键队列3-4级治疗中出现的不良事件最常见为中性粒细胞减少32/128(25%);1-2级细胞因子释放综合征83/128(65%),3级细胞因子释放综合征2/128(2%)。
- 关键队列免疫效应细胞相关神经毒性综合征8/128(6%)(1级5例[4%];2级3例[2%])。
- 2022年10月25日至2024年1月8日,周期1优化队列入组并治疗86例患者(中位年龄64岁[55-71];女性37例[43%],男性49例[57%])。
关键数值与推荐
- 关键队列总缓解率82.0%(105/128,95%CI 74.3-88.3),完全缓解率62.5%(80/128,95%CI 53.5-70.9)。
- 关键队列3-4级中性粒细胞减少32/128(25%),1-2级细胞因子释放综合征83/128(65%),3级细胞因子释放综合征2/128(2%)。
- 关键队列免疫效应细胞相关神经毒性综合征8/128(6%)(1级5例[4%],2级3例[2%])。
- 周期1优化队列细胞因子释放综合征发生率49%(42/86;2级8例[9%];无3级或以上),无免疫效应细胞相关神经毒性综合征报告。
临床怎么用
- 原文结论认为epcoritamab单药在多次复发或难治性滤泡性淋巴瘤中显示出有临床意义的活性,安全性可控。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A standard of care and optimal duration of therapy have not been established for patients with multiply relapsed or refractory follicular lymphoma. The aim of this study was to evaluate epcoritamab, a novel CD3 × CD20 bispecific antibody, in the third-line and later setting of follicular lymphoma. METHODS: EPCORE NHL-1 is a multicohort, single-arm, phase 1-2 trial conducted at 88 sites across 15 countries. Here, we report the primary analysis of patients with relapsed or refractory follicular lymphoma in the phase 2 part of the trial, which included the pivotal (dose expansion) cohort and the cycle 1 optimisation cohort. Eligible patients were aged 18 years or older, had relapsed or refractory CD20+ follicular lymphoma (grade 1-3A), an Eastern Cooperative Oncology Group performance status of up to 2, and had received at least two previous lines of therapy (including an anti-CD20 monoclonal antibody and an alkylating agent or lenalidomide). Patients were treated with subcutaneous epcoritamab 48 mg in 28-day cycles: weekly in cycles 1-3, biweekly in cycles 4-9, and every 4 weeks until disease progression or unacceptable toxicity. To mitigate the risk and severity of cytokine release syndrome, in the pivotal cohort, cycle 1 consisted of a step-up dosing regimen of a 0·16-mg priming dose on day 1 and a 0·80-mg intermediate dose on day 8, followed by subsequent 48-mg full doses and prophylactic prednisolone 100 mg; in the cycle 1 optimisation cohort, a second intermediate dose of 3 mg on day 15, adequate hydration, and prophylactic dexamethasone 15 mg were evaluated during cycle 1 to further reduce risk and severity of cytokine release syndrome. Primary endpoints were independently reviewed overall response rate for the pivotal cohort and the proportion of patients with grade 2 or worse and any-grade cytokine release syndrome for the cycle 1 optimisation cohort. Analyses were done in all enrolled patients who had received at least one dose of epcoritamab. This study is registered with ClinicalTrials.gov, NCT03625037, and is ongoing. FINDINGS: Between June 19, 2020, and April 21, 2023, 128 patients (median age 65 years [IQR 55-72]; 49 [38%] female and 79 [62%] male) were enrolled and treated in the pivotal cohort (median follow-up 17·4 months [IQR 9·1-20·9]). The overall response rate was 82·0% (105 of 128 patients; 95% CI 74·3-88·3), with a complete response rate of 62·5% (80 of 128; 95% CI 53·5-70·9). The most common grade 3-4 treatment-emergent adverse event was neutropenia in 32 (25%) of 128 patients. Grade 1-2 cytokine release syndrome was reported in 83 (65%) of 128 patients; grade 3 cytokine release syndrome was reported in two (2%). Immune effector cell-associated neurotoxicity syndrome was reported in eight (6%) of 128 patients (five [4%] grade 1; three [2%] grade 2). Between Oct 25, 2022, and Jan 8, 2024, 86 patients (median age 64 years [55-71]; 37 [43%] female and 49 [57%] male) were enrolled and treated in the cycle 1 optimisation cohort. The incidence of cytokine release syndrome was 49% (42 of 86 patients; eight [9%] grade 2; none of grade 3 or worse), with no reported immune effector cell-associated neurotoxicity syndrome. INTERPRETATION: Epcoritamab monotherapy showed clinically meaningful activity in patients with multiply relapsed or refractory follicular lymphoma, and had a manageable safety profile. FUNDING: Genmab and AbbVie.
引用
- Linton KM, Vitolo U, Jurczak W, et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024. PMID: 38889737. doi:10.1016/S2352-3026(24)00166-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。